Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study

Table 3

RSV-related respiratory disease characteristics of hospitalized infants during a total of 5 seasons.

Variables	Total babies (N = 925)	<32 weeks (N = 410)	32–35 weeks (N = 515)	value
Compliance (received prophylaxis as per guidelines), N (%)	841 (90.90%)	372 (90.80%)	469 (91%)	0.84
Babies hospitalized (from compliance babies), N (%)	75/841 (8.91%)	45/372 (12.01%)	30/469 (6.39%)	0.04
RSV positive among compliance babies, N (%)	17/841 (2.02%)	9/372 (2.41%)	8/469 (1.70%)	0.46
RSV positive among hospitalized babies (compliance babies), N (%)	17/75 (22.66%)	9/45 (20%)	8/30 (26.66%)	0.50
Total hospitalized baby (from at-risk population), N (%)	87/925 (9.40%)	51/410 (12.43%)	36/515 (6.99%)	0.03
RSV positive in all at risk babies, N (%)	21/925 (2.27%)	11/410 (2.68%)	10/515 (1.94%)	0.45
RSV positive among at risk hospitalized babies, N (%)	21/87 (24.13%)	11/51 (21.56%)	10/36 (27.77%)	0.50
Babies hospitalized (noncompliance babies), N (%)	12/84 (14.28%)	6/38 (15.78%)	6/46 (13.04%)	0.50
RSV positivity in babies not received palivizumab, N (%)	4/84 (4.76%)	2/38 (5.26%)	2/46 (4.3%)	0.80
RSV-related length of stay, days median (IQR)	7.9 (4.6)	10.8 (6.0)	5 (3.2)	0.15
RSV-related PICU admission, N (%)	4/17 (23.50%)	3/9 (33.30%)	1/8 (12.50%)	0.32
Age at the 1st dose of palivizumab for RSV hospitalized babies, months median (IQR)	2.1 (1.3)	2.8 (1.5)	1.5 (1.0)	0.26
Age at hospital admission, months median (IQR)	2.35 (1.35)	3.1 (1.6)	1.6 (1.1)	0.30

RSV, respiratory syncytial virus; IQR, interquartile range; PICU, pediatric intensive care unit.